INFLAZOME
Inflazome is a biotech company that develops orally available drugs to address inflammatory diseases by targeting inflammasomes. The company's drugs block inflammasome signals, eliminating a root cause of inflammation, enabling healthcare institutions to avail targeted therapies for inflammatory diseases such as Parkinson's, Alzheimer's, atherosclerosis, and type 2 diabetes. The company was incorporated in 2016 and is headquartered in Dublin, Ireland.
INFLAZOME
Industry:
Biopharma Biotechnology Health Diagnostics
Founded:
2016-01-01
Address:
Dublin, Dublin, Ireland
Country:
Ireland
Website Url:
http://www.inflazome.com
Total Employee:
11+
Status:
Active
Contact:
+35316798591
Email Addresses:
[email protected]
Total Funding:
63.82 M USD
Technology used in webpage:
SPF LetsEncrypt Apache Euro Microsoft Exchange Online Office 365 Mail Akamai DNS
Similar Organizations
Cellestia
Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression.
Lucira Health
Lucira Health is a biotechnology company that offers disposable test kits to detect RNA and DNA of infectious diseases.
Innovent Biologics
Innovent Biologics is a biopharmaceutical company that develops and manufactures monoclonal antibodies.
Current Employees Featured
Founder
Investors List
Michael J. Fox Foundation
Michael J. Fox Foundation investment in Grant - Inflazome
Forbion Capital Partners
Forbion Capital Partners investment in Series B - Inflazome
Fountain Healthcare Partners
Fountain Healthcare Partners investment in Series A - Inflazome
Novartis Venture Fund
Novartis Venture Fund investment in Series A - Inflazome
Official Site Inspections
http://www.inflazome.com
- Host name: 172.67.205.102
- IP address: 172.67.205.102
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Inflazome"
Inflazome - Crunchbase Company Profile & Funding
Inflazome is a biotech company that develops orally available drugs to address inflammatory diseases by targeting inflammasomes. The company's drugs block inflammasome signals, …See details»
Inflazome Announces Acquisition by Roche - Business Wire
Sep 21, 2020 With Inflazome now part of the Roche organization, Inflazome’s pioneering molecules are well positioned to be developed quickly and effectively so they can help patients …See details»
Inflazome Company Profile - Office Locations, Competitors ... - Craft
Sep 21, 2020 Inflazome engages in developing orally available drugs to address clinical unmet needs in inflammatory diseases by targeting the inflammasome. The Company is developing …See details»
Inflazome - Company Profile - Tracxn
3 days ago Inflazome - Developer of inhibitors for the treatment of chronic inflammatory diseases. Acquired by Roche. Raised a total funding of $65M over 3 rounds from 5 investors. …See details»
Inflazome - Org Chart, Teams, Culture & Jobs | The Org
View Inflazome's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Inflazome Announces Acquisition by Roche - BioSpace
Sep 21, 2020 Inflazome is a pioneering inflammasome company developing orally available NLRP3 inflammasome inhibitors to address clinical unmet needs across a wide variety of …See details»
Forbion portfolio company, Inflazome acquired by Roche
Sep 21, 2020 We are delighted to have been part of Inflazome’s journey and will follow the development of Inflazome‘s promising compounds with great interest.” Lazard acted as …See details»
Inflazome announces acquisition by Roche - Shake It Up Australia …
Sep 22, 2020 Shake It Up co-funded the initial trial with Inflazome to target inflammation in the brain. The company has now been acquired by Roche. Donate. About Us. Our Vision, Mission …See details»
Inflazome - Funding, Financials, Valuation & Investors - Crunchbase
Inflazome is a biotech company that develops orally available drugs to address inflammatory diseases by targeting inflammasomes. Search Crunchbase. ... How much funding has this …See details»
Inflazome - Recent News & Activity - Crunchbase
Inflazome is a biotech company that develops orally available drugs to address inflammatory diseases by targeting inflammasomes. Search Crunchbase. Start Free Trial . Chrome …See details»
Roche bulks up in inflammation with €380m Inflazome acquisition
4 days ago Inflazome meanwhile emerged onto the scene in 2016, coming out of stealth mode with a $17 million Series A financing backed by Novartis’ venture capital arm, and following …See details»
Roche pays €380M for NLRP3 biotech Inflazome ... - Fierce Biotech
Sep 21, 2020 Roche has bought Inflazome for €380 million ($451 million) upfront to gain control of treatments for inflammatory diseases. The deal gives Roche full rights to a pipeline of oral …See details»
Inflazome - VentureRadar
Similar Companies: NodThera United Kingdom Privately Held NodThera is unlocking the significant therapeutic potential of NLRP3 inflammasome activation inhibitors through our …See details»
Team — Inflazome
Luke O’Neill is Inflazome’s Chief Scientific Officer as well as Professor of Biochemistry, Trinity College Dublin. His 18-person research lab focuses on the molecular basis to inflammation. …See details»
Inflazome announces acquisition by Roche
Sep 21, 2020 Inflazome announces acquisition by Roche. Inflazome is a pioneering inflammasome company developing orally available NLRP3 inflammasome inhibitors to …See details»
Science - Inflazome
Inflazome was co-founded in 2016 by globally recognised academic scientists, Prof Matt Cooper (University of Queensland) and Prof Luke O’Neill (Trinity College Dublin) following a highly …See details»
Inflazome - Contacts, Employees, Board Members, Advisors
Inflazome is a biotech company that develops orally available drugs to address inflammatory diseases by targeting inflammasomes. ... Products. Resources. Pricing. Resources. Log In. …See details»
INFLAZOME: FDA Grants Orphan Drug Designation for Inflazome’s …
Jul 17, 2020 Inflazome has two clinical-stage investigational drugs. Inzomelid is under development as an orally available, brain-penetrant drug and Somalix is under development …See details»
Inflazome - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Nov 10, 2024 Inflazome uses 5 technology products and services including HTML5, Google Fonts, and Microsoft Outlook, according to G2 Stack. Inflazome is actively using 20 …See details»
FDA Grants Orphan Drug Designation for Inflazome’s ... - BioSpace
Jul 14, 2020 DUBLIN & CAMBRIDGE, England & BRISBANE, Australia--(BUSINESS WIRE)-- Inflazome (inflazome.com), the pioneering inflammasome biotech company developing …See details»